Welcome to Diopsys, Inc.
The World Leader in Modern Visual Electrophysiology
Diopsys is the leader in electroretinography (ERG) and visual evoked potential (VEP) for the eye care practice. The company’s unique, patented technology provides ophthalmologists and optometrists with objective, functional information about the health of the vision system to aid in the early detection of vision disorders, and post-treatment tracking for enhanced patient management.
Diopsys® ERG and VEP tests can be performed on the Diopsys® NOVA (cart) or Diopsys® ARGOS™ (tabletop) system.
The company understands the important role of early medical intervention for correctable vision problems, which can lead to an improved quality of life.
Early detection means better patient outcomes.
The VEP results correlated significantly with the severity of visual field damage, but the results were obtained objectively, which helps give eye care specialists more confidence in the findings.
Pattern ERG is a technology that allows us to have earlier diagnosis or confirmation of glaucoma than anything else that we currently use.
In my 40 some years in this business, this is the first time that we’ve been able to get real, objective evidence of how the retina’s doing in a host of conditions.
In my world, I’m testing patients with cataracts, glaucoma, macular degeneration, and retinal pathology. It’s not your typical assumption of what electrophysiology would be, and I think that’s the beauty of the Diopsys® NOVA™ system. It’s allowing doctors like me to be able to take this technology and actually elucidate a lot of these problems in our practice.
We had two ways to measure structure with an HRT and OCT, but only one very subjective way to measure function with a visual field. Now with the Diopsys®NOVA™ ERG and VEP Vision Testing System we have a very repeatable, reliable, objective way to measure function and give balance to our clinical decision making.
A game-changer in glaucoma diagnostics (Diopsys®NOVA™) is technology that utilizes ERG and VEP in-office to detect ganglion cell suffering prior to damage that is permanent and irreversible.
I have had the Diopsys device for over two years and I use it every day. The information it gives me is invaluable. The glaucoma suspects, those patients with ‘unexplained vision loss,’ AMD, Plaquenil and Diabetic patients – they all benefit from the technology. It has made me a much better clinician and would recommend it to all my colleagues.
The holy grail for glaucoma or all forms of progressive optic neuropathy is to be able to answer, ‘is the problem in the retina or is the problem in the visual pathway behind the eye?’ Now there’s a way of doing this that we didn’t have before (with the Diopsys® NOVA™). Not only is it helping us understand today’s patient, but it’s going to help us develop new therapies that will save a lot of morbidity and save a lot of sight in our own lifetime.
Five years ago, there were conditions that I never would have used electrophysiology for. Now we run many of our glaucoma patients, and many of our plaquenil patients through our electrophysiology clinic. The Diopsys® NOVA™ ERG and VEP Vision Testing System has really transformed how we use these tests.
We are using the Diopsys® NOVA™ ERG and VEP Vision Testing System in a variety of patients. We’re using it in patients with low tension glaucoma where it’s difficult to ascertain what’s happening because they have a “normal” pressure. They may have a totally normal visual field, but they have a very abnormal optic disc, so in those patients, this electrophysiologic testing is of great help.
Before we had our Diopsys® NOVA™ ERG and VEP Vision Testing System, I would be hard-pressed to send somebody for an ERG. But with this office-based device, not only can we do these tests more efficiently, now we can explore and handle diseases that we never thought of doing electrophysiology for.
We were looking for another way to measure functional vision other than visual acuity and visual field testing. The Diopsys® NOVA™ system enabled us to get an objective, functional vision measurement without depending on our patients’ subjective responses. It is a great tool in the office for many conditions, but specifically it has been very helpful with our glaucoma suspects. The test results really help as another piece of the puzzle with glaucoma management.
We’ve all had those patients whose visual fields are unattainable or unreliable yet we are still highly suspicious of glaucoma. We perform an OCT, which gives us an idea of the structure of the eye, but we have to put structure and function together. The Diopsys® NOVA™ gives us the functional, objective, reliable data that we can use.
Diopsys has provided me with the VEP diagnostic instrument of both the present and the future. All of the advantages of each of the 5 instruments I have used in 32 years of VEP testing have been integrated into this system. The Diopsys® NOVA™ system has made testing easier to do and easier to present to my patients. But most of all, I feel it has given me the ability to collect more reliable responses and enhanced my clinical use of this important measure of sensory function.
A study in Documenta Ophthalmologica showed the Diopsys® NOVA™ is a reliable and reproducible device; making this technology extremely useful for detection of pathologies affecting the entire visual pathway.
Glaucoma is one of our biggest practice growth drivers the last couple of years. The best way to treat glaucoma is to catch it as early as possible in order to alter the disease curve. The Diopsys® NOVA™ Vision Testing System fits into our diagnostic glaucoma suite so elegantly and clinically.
The SD-tVEP results (from the Diopsys® NOVA™) correlated significantly with the severity of visual field damage, but the results were obtained objectively, which helps give eye care specialists more confidence in the findings.
The Diopsys® NOVA™ ERG and VEP Vision Testing System has played an important role in helping us determine how well a patient is responding to therapy. When we lower eye pressure enough or treat these patients appropriately, we can see improvement in function. This technology is very sensitive. When we measure structure, say with OCT, we may not see the improvement.
It’s the only objective test we have in the eye care industry that is able to functionally tell us how the whole visual system is working.